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Introduction 
Platelets play a key and beneficial role for primary hemostasis on 
the disruption of the integrity of vessel wall. Platelets adhere to the 
exposed subendothelial collagen through the interaction of circul-
ating von Willebrand factor and glycoprotein (GP) Ib-IX-V complex, 
a major platelet membrane receptor responsible for adhesion. 
After the adhesion of platelets to the subendothelial collagen, pla-
telets become activated. Activation processes of platelets include 
the release of adenosine diphosphate (ADP) from dense granules, 
the synthesis of thromboxane A2 (TXA2) via a series of enzymatic re-
actions, and thrombin formation via a coagulation cascade. In ad-
dition, ADP is released from endothelial cells at the site of vascular 
injury. Binding of these mediators to G protein-coupled receptors of 
platelet membrane, changes the shapes of platelets from smooth 
discs to irregular spheroids with extrusion of filopodia, and activates 
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platelet membrane GP IIb/IIIa receptors through complex signal 
transduction mechanisms. Activated GP IIb/IIIa binds to fibrinogen, 
finally forming platelet aggregates.
1)2) 
Platelet aggregation is not only an essential part of hemostasis, 
but also initiates acute coronary syndrome or ischemic stroke. Re-
cent efforts to prevent the development of unstable angina or acute 
myocardial infarction from stable atheromatous plaques, and th-
rombotic complications related to percutaneous coronary inter-
vention progress the understanding of mechanisms of platelet ac-
tivation, but its precise mechanism and related proteins are not fully 
identified. This review will focus on the recent progress of knowledge 
about platelet activation mechanism.
Mediators of Platelet Activation
Adenosine diphosphate
Adenosine diphosphate and its analogues bind to P2 receptors, 
which are expressed ubiquitously throughout the human body in-
cluding on platelets, on vascular smooth muscle cells, and on en-
dothelial cells. P2 receptors are divided into P2X and P2Y receptors. 
P2X receptors are ligand-gated ion channel receptors, and P2Y re-
ceptors are G-protein coupled receptors. Each subtype of P2X and 
P2Y receptors is classified by the relative potency of purine and 
pyrimidine nucleotides, as agonists, to induce intracellular calcium 
transients or smooth muscle contraction after genetic cloning. 
Seven P2X receptors (P2X1, P2X2, P2X3, P2X4, P2X5, P2X6, and P2X7) 296  Platelet Activation and Integrin αIIβ3
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and P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, and P2Y13) 
are cloned in mammalian cells.
3) Platelets express P2X1, P2Y1, and 
P2Y12 receptors.
4-6)
Adenosine diphosphate binding to P2X1 receptor results in rapid 
extracellular calcium influx, leading to alteration of platelet shape, 
but without platelet activation. ADP-stimulation of Gq-coupled 
P2Y1 receptor activates phospholipase C (PLC) and induces a tran-
sient increase in intracellular calcium concentration resulting in 
platelet shape change and in weak, transient platelet aggregation. 
Stable and firm platelet aggregation requires ADP binding to P2Y12 
receptor and activation of GPIIb/IIIa receptors in the platelets mem-
brane.
7) Activation of Gi-coupled P2Y12 receptor liberates the Gi pro-
tein subunits, αGi and βγ. The subunit αGi decreases the platelet cy-
clic adenosine monophosphate (cAMP) level through the inhibition 
of adenylyl cyclase. This decrease in cAMP production leads, in turn, 
to a reduction in the activation of protein kinase C (PKC), and, after 
complex signal transduction processes, activation of GP IIb/IIIa re-
ceptors (Fig. 1). The subunit βγ activates the phosphatidylinositol 
3-kinase (PI-3K), which regulates protein kinase Akt and contrib-
utes to the activation of GP IIb/IIIa receptors. 
The P2Y12 receptor is inhibited by ticlopidine, clopidogrel, prasu-
grel, or ticagrelor, which are currently used for patients with acute 
coronary syndrome or coronary stents to prevent thrombotic com-
plications.
Thrombin
Thrombin is the most potent activator of platelets. Thrombin for-
mation is initiated by the exposure of tissue factor to the coagula-
tion system after disruption of the vascular endothelium. Thrombin 
formation takes place on cellular surfaces, including the phospho-
lipid membrane of activated platelets, which amplifies coagulation 
processes. Thrombin interacts with protease-activated receptors 
(PARs) on the surface of human platelets, which couple to Gq, G12/G13 
and Gi family of heterotrimeric G proteins.
8) Of the 4 PARs, human 
platelets express PAR1 and PAR4. PAR1 mediates human platelet 
activation at low thrombin concentrations, whereas PAR4 induces 
platelet activation only at high thrombin concentrations.
9)
Thrombin binding of PARs initiates the cleavage of the extracel-
lular domain of the receptor and exposure of a tethered ligand at 
the new end of the receptor. Signaling through either PAR uses PLC 
pathway and PKC pathway, leading to the activation of GP IIb/IIIa 
receptors.
10) In addition, interaction of thrombin with PARs causes 
the production of TXA2, the release of ADP, and generation of more 
thrombin on the platelet surface. 
Vorapaxar is an oral reversible PAR1 antagonist. In a phase 2 trial, 
vorapaxar showed a trend toward lower incidence of major adverse 
cardiovascular events (MACE) without differences of major and mi-
nor bleeding in patients scheduled for angiography and possible 
coronary stenting.
11) However, in a recent large randomized clinical 
trial, the addition of vorapaxar to standard therapy in patients with 
non-ST elevation acute coronary syndrome did not reduce MACE 
but significantly increased the risk of major bleeding, including in-
tracranial hemorrhage.
12) 
Thromboxane A2
Thromboxane A2 is produced from arachidonic acid through con-
version by cyclooxygenase-1 and thromboxane synthase. Like ADP, 
TXA2 functions as a positive-feedback mediator during platelet ac-
tivation. Human TXA2/prostaglandin (TP) receptor exists in 2 iso-
forms, TPα and TPβ, and human platelets express both isoforms.
13) 
TP receptor couples to Gq and G12/G13. TXA2 stimulation of Gq pro-
teins causes activation of PLC, resulting in accumulation of inositol-
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). Stimulation of 
G12/G13 proteins activates Rho signaling. TP receptor-mediated pl-
atelet shape change is mainly dependent on G12/G13, while aggre-
gation is dependent on Gq.
14)
 
Platelet Integrins
Integrins are a widely expressed family of heterodimeric trans-
membrane receptors linking extracellular ligands to intracellular 
signaling pathways and contributing to a wide variety of physio-
Fig. 1. ADP receptors in the platelet. ADP binding to P2X1 receptor results 
in rapid extracellular calcium influx, leading to alteration of platelets shape. 
ADP-stimulation of Gq-coupled P2Y1 receptor activates phospholipase C 
resulting in weak, transient platelet aggregation. Activation of Gi-coupled 
P2Y12 receptor inhibits protein kinase C, and activates phosphatidylinositol 
3-kinase, resulting in the activation of GP IIb/IIIa receptors and firm plate-
let aggregation. P2Y12 receptors are inhibited by ticlopidine or clopidogrel. 
AC: adenylyl cyclase, ADP: adenosine diphosphate, cAMP: cyclic adenosine 
monophosphate, GP: glycoprotein, PI3K: phosphatidylinositol 3-kinase, 
PLC: phospholipase C, PKC: protein kinase C.297 Seung-Jae Joo
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logical processes. They are composed of α- and β-subunits, which 
are non-covalently linked to each other. Both subunits consist of a 
large N-terminal extracellular domain forming a globular head, a 
single transmembrane domain and a short cytoplasmic tail do-
main. Platelets express 3 different β1-integrins: α2β1 (collagen re-
ceptor), α5β1 (fibronectin receptor), and α6β1 (laminin receptor); 
and 2 β3-integrins: αIIbβ3 and αvβ3. Although integrin α2β1 is as-
sociated with platelet adhesion to the injured vessel wall, the domi-
nant integrin on the platelet surface is αIIbβ3, which mediates pla-
telet aggregation.
15)16)
 Integrin αIIbβ3 is present 60,000-80,000 copies per resting 
platelet, which is the highest density of all platelet membrane pro-
teins. The membranes of platelet α-granules contain αIIbβ3 that 
becomes externalized on platelet secretion to increase the surface 
expression of αIIbβ3 by 25% to 50%. The αIIb subunit consists of 
1008 amino acids, which is composed of a heavy and a light chain. 
The light chain contains a 20-amino acid cytoplasmic tail, a trans-
membrane helix, and an extracellular segment that is a disulfide 
linked to the heavy chain, which is entirely extracellular. The β3 sub-
unit is a single polypeptide chain of 762 amino acids. The 2 sub-
units assemble into the divalent, cation-dependent heterodimer 
during biosynthesis in megakaryocytes (Fig. 2).
17)18)
The ligands of αIIbβ3 include fibrinogen, fibronectin, von Wille-
brand factor, and vitronectin. Fibrinogen and von Willebrand factor 
support platelet aggregation. Integrin αIIbβ3 recognizes Arg-Gly-
Asp (RGD) sequence of the ligands. The most important character-
istic of integrin αIIbβ3 is the affinity modulation after its activa-
tion. In resting platelets, the affinity of αIIbβ3 for fibrinogen, a main 
ligand of platelet aggregation, is low, and minimal binding occurs 
despite the high levels of fibrinogen in blood. Activation of integrin 
αIIbβ3 depends primarily on the conformational change of the re-
ceptors, whether induced by platelet adhesion to extracellular ma-
trix, or agonists, such as ADP, thrombin, or arachidonic acid. This re-
quires transmission of information from within the cell to the ex-
tracellular domain of αIIbβ3, a process referred to as “inside-out” sig-
naling, which changes receptors from a low- to high-affinity state 
(Fig. 3A). Integrin activation can involve changes not only in affinity 
for ligand, but also in avidity for ligand, a consequence of receptor 
clustering. Both mechanisms can lead to activation of αIIbβ3, but 
affinity modulation is dominant. Platelet activation leads to a mar-
ked increase in the affinity of αIIbβ3 for fibrinogen. Ligand-occupied 
integrin αIIbβ3, on the other hand, triggers various cellular proces-
ses, such as reorganization of the cytoskeleton within platelets, th-
rough “outside-in” signaling (Fig. 3B).
17)
Activation Mechanism of Integrin αIIbβ3
The activation mechanism of integrin αIIbβ3 from a low- to 
high-affinity state has been intensively studied because this signal 
transduction pathway may be a potential target for a new antith-
rombotic agent. Conformational changes of the extracellular do-
Fig. 2. A schematic structure of platelet integrin αIIbβ3. The αIIb subunit is 
composed of a heavy and a light chain. The light chain contains a cytoplas-
mic tail, a transmembrane helix, and an extracellular segment that is disul-
fide linked to the heavy chain, which is entirely extracellular. The β3 subunit 
is a single polypeptide chain. The 2 subunits assemble into the divalent, 
cation-dependent heterodimer.
Fig. 3. “Inside-out” and “outside-in” signaling of integrin αIIbβ3. A: platelet adhesion to extracellular matrix, or agonists, such as ADP, thrombin, or arachi-
donic acid, initiate platelet activation process that requires transmission of information from within the cell to the extracellular domain of αIIbβ3, a pro-
cess referred to as “inside-out” signaling, which changes receptors from a low- to high-affinity state. B: ligand-occupied integrin αIIbβ3 triggers various 
cellular processes within platelets, through “outside-in” signaling.
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mains of integrin αIIbβ3 and resulting affinity modulation are ini-
tiated by the interaction at the cytoplasmic tails. Cellular control of 
integrin activation requires transmission of a signal from the small 
cytoplasmic tails to the large extracellular domains. The exact me-
chanism involved in inside-out and outside-in signaling of integrin 
αIIbβ3 is not fully understood, and the functional significance of the 
related proteins is still evolving (Fig. 4).
10)16)
Rap1b/CalDAG-GEFI
Recent studies have emphasized the role of the Rap family of 
small GTPases in inside-out signaling of integrin activation. Rap1b 
is the most abundant Ras family member in platelets.
19) Rap1b de-
ficiency in murine platelets showed reduced platelet aggregation, 
decreased activation of integrin αIIbβ3, and protection from arte-
rial thrombosis.
20) Rap proteins cycle between GDP-bound inactive 
form and GTP-bound active form. GTP binding to Rap is facilitated 
by guanine nucleotide exchange factors (GEFs). In platelets, Rap1b 
is controlled by Ca
2+ and diacylglycerol-regulated guanine nucleo-
tide exchange factor I (CalDAG-GEFI), which contains binding sites 
for Ca
2+ and DAG, and a GEF domain.
21) The importance of CalDAG-
GEFI was demonstrated in CalDAG-GEFI-deficient mice. Cal-DAG-
GEFI deficiency resulted in impaired platelet aggregation responses 
to ADP or TXA2, but not to collagen or thrombin.
22) CalDAG-GEFI
-/- 
mice showed prolonged bleeding time and protection against ex-
perimental thrombosis. 
Different agonist responses in CalDAG-GEFI-deficient platelets 
suggest the existence of a CalDAG-GEFI-independent mechanism 
of integrin αIIbβ3 activation. In murine platelets, PAR4 agonist-in-
duced aggregation in the absence of CalDAG-GEFI required co-
signaling through the αGi-coupled P2Y12 receptor involving PKC. Th-
erefore, PKC was identified as an alternative pathway leading to 
Rap1 and αIIbβ3 activation. It has been proposed that rapid, but re-
versible activation of Rap1 is mediated by CalDAG-GEFI, whereas 
PKC ensures sustained Rap1 activation through its central role in 
the release of ADP from dense granules.
21)
Agonist activation of platelets is usually accompanied by an in-
crease in the cytosolic Ca
2+ concentration, which is required for in-
tegrin activation and releases of the second wave mediators, such 
as ADP or TXA2. The source of Ca
2+ can be either intracellular or ex-
tracellular. Agonists binding of platelet Gq coupled-receptors acti-
vates PLC, which in turn produces inositol 1,4,5-triphosphate (IP3) 
from phosphoinositol biphosphate (PIP2). The intracellular Ca
2+ is re-
leased from the sarcoplasmatic reticulum (SR) by IP3. Because of the 
limited Ca
2+ store of the ER, the major source of an intracellular Ca
2+ 
transient is store-operated Ca
2+ entry (SOCE) of the extracellular 
Ca
2+ through the activation of Ca
2+ release activated calcium chan-
nels (CRAC), Orai1, in the platelets membrane, which are controlled 
by the depletion of SR Ca
2+ stores.
23) Recent studies identified stro-
mal interaction molecule 1 (STIM1) as a key regulator of SOCE into 
platelets.
24) STIM1 is a type I transmembrane protein containing a 
calcium binding EF hand motif, which is occupied by Ca
2+ in resting 
platelets. After platelet activation, Ca
2+ is released from the ER and 
STIM1 is no longer occupied by Ca
2+, resulting in translocation of 
STIM1 within the platelets to allow SOCE by opening the Orai1. 
Platelets of STIM1 or Orai1-deficient mice showed defective SOCE, 
but largely intact agonist-induced integrin activation, demonstrat-
ing that this process can be initiated by relatively small rises in in-
tracellular Ca
2+ transients from the ER.
24)25)
Rap1-GTP-interacting adaptor molecule
The Rap1 effector molecule Rap1-GTP-interacting adaptor mole-
cule (RIAM) is a member of the MRL (Mig-10, RIAM, and lamellipo-
din) family of adaptor proteins.
26) MRL proteins function as scaf-
folds to connect the membrane targeting sequences in Ras GTPases 
to talin-1. This interaction of MRL proteins with both Rap1-GTP and 
talin-1 mediates adhesion of β1 and β2 integrins.
27) In living cells, 
RIAM over-expression stimulates talin recruitment to αIIbβ3 with 
integrin activation,
19) but RIAM knockdown blocks talin recruitment 
to αIIbβ3 with integrin response.
28) These findings suggest the im-
Fig. 4. Molecular mechanisms involved in the activation of integrin αIIbβ3. 
G protein-mediated signaling pathways, which are initiated by Gq or Gi, in-
clude phospholipase C with calcium signaling, protein kinase C (PKC) and 
phosphatidylinositol 3-kinase (PI-3K). Rap1b, Ca
2+ and diacylglycerol-regu-
lated guanine nucleotide exchange factor I (CalDAG-GEFI), Rap1-GTP-in-
teracting adaptor molecule (RIAM), and Akt are important molecules in-
volved in G protein-mediated activation of integrin αIIbβ3. Binding of 
talin-1 and kindlin-3 to cytoplasmic domains of β3-integrin triggers a con-
formational change in the extracellular domains that increases its affinity 
for ligands, such as fibrinogen or von Willebrand factor. AC: adenylyl cy-
clase, CRAC: Ca
2+ release activated calcium channel, ER: endoplasmic retic-
ulum, GSK: glycogen synthase kinase, IP3: inositol 1,4,5-triphosphate, IP3R: 
IP3 receptor, NOS3: nitric oxide synthase 3, PDE: phosphodiesterase, PIP2: 
phosphoinositol biphosphate.299 Seung-Jae Joo
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portant interaction of Rap1-GTP, RIAM and talin-1, resulting in the 
binding of talin-1 to integrin β cytoplasmic tails.
29) 
Akt
PI-3K, via phosphatidylinositol-dependent kinase-1, generates 
phosphoinositide products including Akt, which is a family of in-
tracellular serine/threonine protein kinases (also called protein ki-
nase B).
30) Three isoforms of Akt, which possess more than 80% ho-
mology, have been identified: Akt1, Akt2, and Akt3. Platelets contain 
both the Akt1 and Akt2 isoforms. Platelets from Akt1-deficient mice 
exhibited defects in dense and α-granule secretion, reduced fibrino-
gen binding, and impaired aggregation in response to low concen-
trations of thrombin.
31) Also, Akt2-deficient mice showed impaired 
platelet aggregation, fibrinogen binding, and granules secretion es-
pecially in response to low concentrations of thrombin and TXA2, 
which activate the Gq-coupled receptors.
30) The above findings sh-
owed that both Akt-1 and Akt-2 are important in low dose agonist-
induced platelet activation and in platelet-dependent thrombus 
formation. 
Several signaling molecules have been implicated as the down-
stream targets of PI-3K- and Akt-mediated platelet activation. These 
include glycogen synthase kinase (GSK)-3β, nitric oxide synthase 
(NOS) 3, and cAMP-dependent phosphodiesterase (PDE3A). GSK-
3β suppresses platelet function and thrombosis in mice. Akt-medi-
ated phosphorylation of GSK-3β inhibits its suppressive function 
of platelet activation.
32) Akt-mediated stimulation of NOS3 induces 
protein kinase G-dependent degranulation of platelets.
33) In addition, 
Akt has been implicated in activation of PDE3A, resulting in re-
duced platelet cAMP levels after thrombin stimulation.
34) 
Talin-1
Talin is one of several proteins that link the cytoplasmic domains 
of integrin β subunits to actin filaments. Binding of talin to cyto-
plasmic domains of β-integrins triggers a conformational change 
in the extracellular domains that increases its affinity for ligands.
35) 
Talin-1, a 270-kDa cytoplasmic protein, is composed of a globular 
N-terminal head domain and a flexible rod domain, which can be 
dissociated by the protease calpain 2. The head region of talin-1 con-
tains a FERM (protein 4.1, ezrin, radixin, moesin) domain comprising 
3 subdomains F1, F2, and F3, which has binding sites for the cyto-
plasmic domains of β-integrins, as well as for filamentous actin (F-
actin). The talin rod contains an additional integrin-binding site, at 
least 2 actin-binding sites and several binding sites for vinculin.
36) 
The cytoplasmic domains of β-integrins are essential for integrin 
activation. The β3 tail interacts with a large number of cytosolic pro-
teins to induce the conformational change of the extracellular do-
main. To identify structural features responsible for these interac-
tions, nuclear magnetic resonance (NMR) studies about β3 trans-
membrane (TM) and cytoplasmic domains were performed.
37)38) The 
results of these studies showed 3 α helices followed by a short un-
structured C-terminus. The first helix, β3 TM helix, embedded in 
the lipid bilayer, but oriented at a tilted angle because the length 
of this helix is longer than that of a typical membrane bilayer. The 
β3 TM helix is followed by a hinge at residues H722-D723, the sec-
ond helix (residues K725-A735), a hinge containing NPLY motif (re-
sidues 744-747), and the third helix at the C-terminal end.
In one suggested model for talin-mediated activation of integ-
rins, the low-affinity αIIbβ3 is maintained through the interaction 
between α and β subunit at the TM and membrane-proximal do-
mains. The TM helices specifically pack together and are in a long and 
tilted geometry. The membrane-proximal regions of αIIb and β3 cy-
toplasmic tails are believed to interact through a salt bridge between 
a conserved Arg in the αIIb tail and an Asp in the β3 tail, thereby 
keeping αIIbβ3 in the inactive state. The F3 subdomain of talin FERM 
domain contains a phosphotyrosine binding (PTB) domain, which 
interacts with NPLY motif of β3 tail. This interaction is proposed to 
induce αIIbβ3 activation by disrupting salt bridge formed between 
αIIb-Arg995 and β3-Asp723, and hence inducing a series of confor-
mational changes that give rise to the affinity modulation of the 
extracellular domain.
19)
The analysis of platelets from conditional talin-1-deficient mice 
(Tln
-/-, CreloxP) supported an essential function of talin-1 in platelet 
integrin activation.
39)40) Talin-1-deficient platelets were unable to ac-
tivate integrin αIIbβ3 in response to any tested agonists and con-
sequently did not aggregate. Furthermore, they failed to spread on 
immobilized fibrinogen, suggesting that talin-1 is required for 
αIIbβ3-dependent outside-in signaling, as well as inside-out signal-
ing. This complete lack of integrin function in Tln
-/-platelets resulted 
in defective hemostasis and thrombus formation in injured vessels 
in vivo. 
Kindlin-3
Kindlins constitute a family of evolutionarily conserved cytoplas-
mic components of cell-extracellular matrix adhesions that bind to 
cytoplasmic tails of β-integrins directly and cooperate with talin in 
integrin activation. There are 3 mammalian kindlins: kindlin-1 (also 
known as kindlerin and FERMT1), kindlin-2 (also known as MIG-2) 
and kindlin-3 (also known as URP 2). They exhibit identical domain 
architecture and high sequence similarities. One of the important 
features of kindlins is that they contain a FERM domain, which binds 
to the cytoplasmic tail of β1 and β3 integrins. So far, 2 more kin-
dling binding proteins other than β integrins have been identified: 
integrin-linked kinase (ILK) and migfilin.
41)
It is proposed that the PTB site of the F3 domain in kindlin-3 di-300  Platelet Activation and Integrin αIIβ3
http://dx.doi.org/10.4070/kcj.2012.42.5.295 www.e-kcj.org
rectly interacts with the NITY motif (residues 756-759) located just 
after the 3rd helix of integrin β tails.
35) Different binding regions of 
talin-1 and kindlin-3 allow either simultaneous or sequential bind-
ing of the 2 proteins to activate the integrin.
16) 
Platelets from fetal liver cell chimeric kindlin-3
-/- mice were un-
able to activate integrin αIIbβ3 in response to any tested agonist, 
despite unaltered expression of talin-1, and kindlin-3
-/- platelets 
did not spread on fibrinogen. This complete loss of integrin function 
resulted in a severe hemostatic defect and resistance to arterial 
thrombosis in kindlin-3
-/-chimeric mice.
42)
Platelet Aggregation
The final common step leading to the formation of the platelet 
plug is platelet aggregation. Platelet aggregation is mediated by 
the activated GP IIb/IIIa, which binds fibrinogen and von Willebrand 
factor at high affinity. The dimeric structure of fibrinogen and the 
multimeric structure of vWF allow these ligands to act as bridges 
between adjacent platelets and to generate a platelet aggregate.
15) 
GP IIb/IIIa receptor blockers inhibit fibrinogen binding to the re-
ceptors, resulting in the suppression of platelets aggregation (Fig. 5). 
Abciximab, chimerized monoclonal antibody to integrin αIIbβ3 (c7E3) 
to reduce immunogenicity, was the first GPIIb/IIIa receptor blocker 
to be widely used in humans. The peptides recognized by integrin 
αIIbβ3 were used in drug development. Eptifibatide contains the 
amino acid sequence, Lys-Gly-Asp (KGD) within a disulphide ring. 
Tirofiban is a synthetic, non-peptide inhibitor based on RGD se-
quence.
17)18) 
Conclusion
Numerous antiplatelet agents have been developed based on the 
platelet activation mechanism, and some of these agents have been 
being used for the primary and secondary prevention of cardiovas-
cular diseases. Sometimes dual or triple antiplatelet agents, GP IIb/
IIIa antagonists, or more potent drugs, are required to prevent th-
rombotic complications, especially in patients with acute coronary 
syndrome or coronary stents. Receptors and signaling proteins in-
volved in platelet activation are targets for a new antiplatelet agent. 
Through an improved understanding of activation mechanism of pla-
telet and integrin αIIbβ3, more effective antiplatelet therapy can 
be developed. 
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